Alpha Down Electroencephalography (EEG) Neurofeedback for Alcohol Use Disorder: Feasibility Trial

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBrigham and Women's Hospital

About this trial

This pilot study is testing a short brain training program called neurofeedback in adults with alcohol use disorder. Participants will complete three sessions over about one week. The goal is to learn if this approach is easy to complete, well tolerated, and acceptable to participants. We will also explore whether it is associated with changes in alcohol cravings and drinking.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults ages 18-65

Meets DSM-5 criteria for current Alcohol Use Disorder

Willing and able to provide informed consent

Alcohol consumption within the past 30 days

Disqualifiers

History of epilepsy or seizure disorder (excluding uncomplicated alcohol withdrawal seizures)

Current psychosis, mania, or acute suicidality, or any psychiatric condition that would impair the ability to provide informed consent or safely participate

Acute alcohol intoxication at the time of study visits, as determined by -breathalyzer

Pregnancy or breastfeeding

Trial design

Design model

Single group

Treatments tested in this trial

  • EEG Neurofeedback

    Device

    Participants will receive a brief course of EEG-based neurofeedback consisting of three sessions over approximately one week. During each session, scalp electrodes are placed to record brain activity using electroencephalography (EEG). Real-time feedback is provided to guide participants in modulating their brain activity. The neurofeedback protocol targets downregulation of alpha-band activity (8-12 Hz). Training is delivered using a standardized protocol with real-time visual and/or auditory feedback. Each session lasts approximately 20 minutes, with additional time for setup and brief assessments.

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: NeurofeedbackExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Participant retention rate over 1 week

Proportion of participants who complete all study visits

Time frame
one week
2

Proportion of participants experiencing adverse events during neurofeedback sessions over 1 week

Number and severity of adverse events

Time frame
One week
3

Proportion of scheduled neurofeedback sessions completed over 1 week

Proportion of scheduled neurofeedback sessions completed

Time frame
One week

Secondary outcomes

1

Change in alcohol craving (Penn Alcohol Craving Scale [PACS] total score) from baseline to Visit 3 (~1 week)

Alcohol craving will be assessed using the Penn Alcohol Craving Scale (PACS). PACS total scores range from 0 to 30, with higher scores indicating greater alcohol craving. Change in PACS total score from baseline to Visit 3 (\~1 week) will be analyzed.

Time frame
One week
2

Change in alcohol consumption measured by Timeline Follow-Back (TLFB) from baseline (Visit 1) to post-intervention (Visit 3, ~1 week)

Alcohol consumption will be assessed using the Timeline Follow-Back (TLFB) method. Change in number of standard drinks over the assessment period from baseline to the final visit will be analyzed.

Time frame
One week

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: